加入收藏 | 設爲首頁 | English|
您當前的位置:首頁 > 學術交流

北京大學基礎醫學院院長論壇(2018.10.25)

時間:2018-10-23 14:56:07  来源:  作者:

報告題目:Exploring Precision Oncology: From DNA Repair Defects to Genomic Instability

報告人:Dr. Arul M. Chinnaiyan, M.D., Ph.D.

S.P. Hicks Endowed Professor of Pathology

Director, Michigan Center for Translational Pathology

The University of Michigan Medical School

  間:20181025日(星期四) 上午9:30-10:30

  點:國際合作處2樓會議室

主持人:尹玉新教授

報告人簡介:

Dr. Chinnaiyan’s research expertise is in functional genomic, proteomic and bioinformatics approaches to study cancer for the purposes of understanding cancer biology as well as to discover clinical biomarkers. The landmark study from his lab was the discovery of TMPRSS2-ETS gene fusions in prostate cancer in 2005.  This finding redefined the molecular basis of prostate cancer as well as other common epithelial cancers. He also led the development of the popular cancer profiling bioinformatics resource called Oncomine (www.oncomine.org).  Most recently, he has been involved in developing high-throughput clinical sequencing approaches for precision oncology (i.e., MI-ONCOSEQ). This has led to a number of discoveries including the pathognomomic gene fusion for solitary fibrous tumor (SFT), etc. Moreover, the mutational landscape of metastatic castration-resistant prostate cancer and diverse adult and pediatric cancers have been analyzed through this study. Recently, his team demonstrated that integrative sequence analysis provides clinically relevant, multidimensional view of the complex molecular landscape and microenvironment of metastatic cancers. The manuscript presenting the analysis of the MET500 cohort was published in Nature and featured on the cover of the journal.

Dr. Chinnaiyan’s lab has also been devoting considerable effort towards understanding the role of long non-coding RNAs (lncRNA) and exploring their clinical potential. One of the lncRNAs that has been extensively studied in the lab, SChLAP1, was associated with a higher risk for biochemical recurrence, metastases, death from prostate cancer, and death from any cause at 10 years after prostatectomy. They showed that non-invasive detection of SChLAP1 in urine is feasible and are currently developing SChLAP1 as a clinical biomarker.

歡迎各位老師及同學參加!

 

800.jpg

來頂一下
返回首頁
返回首頁
發表評論 共有條評論
用戶名: 密碼:
驗證碼: 匿名發表